Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from abroad.
Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from abroad.
Eli Lilly (LLY.N), said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial.
Abbott Laboratories ABT-0.90% declined slightly in premarket trading Wednesday after the healthcare company posted first-quarter sales that missed Wall Street expectations.
J&J beat quarterly profit and revenue expectations and raised its dividend but didn’t change its profit outlook, and the stock pulled back.
Οι εφαρμογές θα εστιάζουν στη διαχείριση του πόνου με βάση τις εγκεκριμένες ενδείξεις των αντίστοιχων φαρμάκων, συμπεριλαμβανομένων των τελικών προϊόντων φαρμακευτικής κάνναβης .
Pfizer stock fell after suffering a setback developing a new weight-loss drug.
A U.S. bankruptcy judge on Monday rejected Johnson & Johnson’s (JNJ.N), opens new tab $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company’s bankruptcy strategy has failed in court.
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease.
Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.
Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.
Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Johnson & Johnson plans to spend over $55 billion to build four plants in the U.S., it said on Friday, as a threat of drug import duties from the Trump administration forces companies to expand their manufacturing operations domestically.
Σε 61,01 εκατ. ευρώ ανήλθαν οι ενοποιημένες Πωλήσεις από συνεχιζόμενη δραστηριότητα, προ Rebate & Clawback της Lavipharm παρουσιάζοντας αύξηση κατά 12,3%.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement.
Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug.
Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market.
Novo Nordisk on Wednesday said it will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy.
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services Department was re-evaluating its $590 million contract to develop a bird flu vaccine.
Novavax stock is rising after the vaccine maker posted quarterly results above analysts expectations early Thursday.